Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA II: FDA Prefers A ‘Manageable Number of High-Impact Changes’

This article was originally published in The Pink Sheet Daily

Executive Summary

Negotiations for generic drug user fee reauthorization open with FDA saying it doesn't want a large number of small tweaks that will increase program complexity.


Related Content

Generic User Fee Negotiations May Be Falling Behind Schedule
Review Times Remain A GDUFA II Topic
Senate Medical Innovation Bill: Will Slow, Small And Steady Win The Race?
GDUFA II: Priority Reviews Considered For Some ANDAs
FDA Generic Office Director Uhl Returns From Medical Leave
GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table
Generic User Fee Waivers Created In Draft House Bill, Breaking FDA-Industry Agreement
FDA's Generic Drugs Office Faces Transition As Director Buehler Departs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts